Global Metastatic Melanoma Therapeutics Market Anticipates Robust Growth with New Therapeutic Developments
March 27, 2024 15:46 ET
|
Research and Markets
Dublin, March 27, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Melanoma Therapeutics Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. Market Growth and...
Global Melanoma Treatment Market Report to 2027 - Growing Regulatory Approvals are Driving the Industry
July 14, 2022 04:38 ET
|
Research and Markets
Dublin, July 14, 2022 (GLOBE NEWSWIRE) -- The "Melanoma Treatment Market - Forecasts from 2022 to 2027" report has been added to ResearchAndMarkets.com's offering. In recent years, there has been a...
Revolution Medicines to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
June 02, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 12, 2020 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
TESARO Announces Collaboration to Evaluate ZEJULA® in Combination With Anti-PD-L1 Cancer Immunotherapy and MEK Inhibitor in Platinum-Sensitive Ovarian Cancer
June 05, 2018 08:30 ET
|
TESARO, Inc.
WALTHAM, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into a clinical collaboration with...